Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1984000006) ANTI-TUMOUR PHARMACEUTICAL PREPARATION
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1984/000006 International Application No.: PCT/RO1982/000004
Publication Date: 05.01.1984 International Filing Date: 18.06.1982
IPC:
A61K 31/05 (2006.01) ,A61K 31/135 (2006.01) ,A61K 31/60 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
045
Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
05
Phenols
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
13
Amines, e.g. amantadine
135
having aromatic rings, e.g. methadone
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
60
Salicylic acid; Derivatives thereof
Applicants:
Inventors:
Priority Data:
null30.12.1899null
Title (EN) ANTI-TUMOUR PHARMACEUTICAL PREPARATION
(FR) PREPARATION PHARMACEUTIQUE ANTI-TUMORALE
Abstract:
(EN) Drug for the treatment of cancer or some other forms of tumours. The drug is composed of 10...350 mg of hydroquinone, 30...200 mg of metol, 10...100 mg of amidol; these three active ingredients may be or not associated with 10...100 mg of paraminosalicylic acid; the quantities are expressed per unidose and the association ratio (by weight) between hydroquinone and metol is comprised between 1:3...7:4. The drug is toxicity-free in the dosage limits stipulated in the present invention.
(FR) Mécicament destiné au traitement du cancer ou autres formes de tumeurs. Le médicament se compose de 10 à 350 mg d"hydroquinone, de 30 à 200 mg de métol, de 10 à 100 mg d"amidol; ces trois ingrédients actifs peuvent être associés à 10-100 mg d"acide paraminosalicilique ou peuvent ne pas l"être; les quantités sont exprimées par unidose et le rapport d"association (en poids) entre l"hydroquinone et le métol est compris entre 1:3 et 7:4. Le médicament n"est pas toxique dans les limites de dosage stipulées dans la présente invention.
Designated States:
Publication Language: French (FR)
Filing Language: French (FR)
Also published as:
EP0112329